Restructuring Charges	9 Months Ended
Sep. 30, 2012
Restructuring Charges	10. RESTRUCTURING CHARGES In February 2012, the Company realigned its business structure and implemented a number of strategic and operational initiatives. As part of these initiatives, the Company terminated certain early stage, preclinical research and development programs and a workforce reduction was implemented. As a result of the restructuring, during the nine months ended September 30, 2012, the Company recorded one-time charges of approximately $1.4 million, which included severance and benefits related charges of approximately $1.2 million, outplacement costs of approximately $120,000, stock compensation expense of $56,000 for amendments to the exercise schedules to certain options and other exit costs of $90,000. All restructuring costs are expected to be paid by December 31, 2012, including $139,000 which is accrued and unpaid as of September 30, 2012. No additional charges are expected in future periods related to this restructuring.

Restructuring Charges

9 Months Ended

Sep. 30, 2012

10. RESTRUCTURING CHARGES

In February 2012, the Company realigned its business structure and implemented a number of strategic and operational initiatives. As part of these initiatives, the Company terminated certain early stage, preclinical research and development programs and a workforce reduction was implemented. As a result of the restructuring, during the nine months ended September 30, 2012, the Company recorded one-time charges of approximately $1.4 million, which included severance and benefits related charges of approximately $1.2 million, outplacement costs of approximately $120,000, stock compensation expense of $56,000 for amendments to the exercise schedules to certain options and other exit costs of $90,000. All restructuring costs are expected to be paid by December 31, 2012, including $139,000 which is accrued and unpaid as of September 30, 2012. No additional charges are expected in future periods related to this restructuring.